Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Citrullinated fibrinogen forms densely packed clots with decreased permeability.

Journal of thrombosis and haemostasis : JTH·2022
Same author

Is it possible to make a common reference standard for D-dimer measurements? Communication from the ISTH SSC Subcommittee on Fibrinolysis.

Journal of thrombosis and haemostasis : JTH·2021
Same author

Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.

Science advances·2021
Same author

An international collaborative study to establish the WHO 3rd International Standard for Thrombin: Communication from the ISTH SSC subcommittee on factor XIII and fibrinogen.

Journal of thrombosis and haemostasis : JTH·2021
Same author

Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.

Proceedings of the National Academy of Sciences of the United States of America·2021
Same author

Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics.

Vox sanguinis·2020

Related Experiment Video

Updated: Nov 17, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.8K

Measuring Fibrinolysis.

Colin Longstaff1

  • 1Department of Biotherapeutics, National Institute for Biological Standards and Control, South Mimms, Herts, United Kingdom.

Hamostaseologie
|February 15, 2021
PubMed
Summary
This summary is machine-generated.

Diagnosing fibrinolysis abnormalities is challenging due to slow physiological fibrinolysis and poorly standardized tests. New methods like viscoelastic testing show promise but lack agreed protocols for clinical use.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K
Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.5K

Related Experiment Videos

Last Updated: Nov 17, 2025

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.8K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K
Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus
06:45

Author Spotlight: Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

2.5K

Area of Science:

  • Hematology
  • Hemostasis and Thrombosis
  • Clinical Pathology

Background:

  • Physiological fibrinolysis is slow compared to rapid coagulation.
  • Current methods for detecting fibrinolysis abnormalities are complex and lack standardization.
  • Existing research on fibrinolysis inhibitors shows mixed conclusions and harmonization issues.

Purpose of the Study:

  • To review the challenges in diagnosing fibrinolysis abnormalities.
  • To discuss the potential and limitations of viscoelastic methods in assessing fibrinolysis.
  • To highlight the impact of SARS-CoV-2 on fibrinolysis assessment.

Main Methods:

  • Review of existing literature on fibrinolysis testing.
  • Discussion of challenges with traditional methods (euglobulin lysis, inhibitor antigen levels).
  • Evaluation of viscoelastic methods for point-of-care testing and whole blood analysis.

Main Results:

  • Standardization issues plague both traditional and D-dimer testing for fibrinolysis.
  • Viscoelastic methods offer rapid, whole-blood analysis but lack standardized protocols for acute care.
  • SARS-CoV-2 associated coagulopathy presents challenges, with high D-dimer levels indicating ongoing fibrinolysis.

Conclusions:

  • Accurate diagnosis of fibrinolysis deficits remains difficult due to methodological limitations.
  • Further standardization of viscoelastic methods is needed for reliable clinical application.
  • Caution is advised when interpreting D-dimer results for prognostic or therapeutic guidance in hyperfibrinolysis.